Prophylaxis of eclamptic seizures: Current controversies

John Repke, S. A. Friedman, P. W. Kaplan

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Treatment of this pathophysiologically poorly understood disease is controversial. Despite this uncertainty, the goals of management of the patient with preeclampsia and eclampsia are diagnosis, stabilization, and delivery of the baby. Stabilization refers to both mother and fetus and should include the prevention of eclampsia or the recurrence of eclamptic seizures. There are empiric data supporting the use of magnesium sulfate for the management of preeclampsia and eclampsia in North America, but there are few data to support its efficacy as a classic anticonvulsant. Until controlled trials are completed, we suggest that magnesium sulfate continue to be used in preeclampsia, with the addition of established anticonvulsant medications when eclampsia occurs. Data on established antiepileptic drugs such as diazepam and phenytoin support their use in treating patients with eclamptic seizures. As stated in an earlier review, 'in treating preeclampsia, magnesium sulfate therapy may have a role and may moderate factors leading to eclampsia. Whether magnesium sulfate therapy may have some as yet unproved effect on epileptogenic foci or seizure propagation is not the important issue for the physician caring for the eclamptic patient. Until adequately designed therapeutic trials are available, it is our opinion that treatment should be based on the use of anticonvulsant drugs of established efficacy in seizure control and prophylaxis (p. 1363).'

Original languageEnglish (US)
Pages (from-to)365-374
Number of pages10
JournalClinical Obstetrics and Gynecology
Volume35
Issue number2
DOIs
StatePublished - Jan 1 1992

Fingerprint

Eclampsia
Magnesium Sulfate
Pre-Eclampsia
Seizures
Anticonvulsants
Therapeutics
Phenytoin
Diazepam
North America
Uncertainty
Fetus
Mothers
Physicians
Recurrence

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Repke, John ; Friedman, S. A. ; Kaplan, P. W. / Prophylaxis of eclamptic seizures : Current controversies. In: Clinical Obstetrics and Gynecology. 1992 ; Vol. 35, No. 2. pp. 365-374.
@article{cf846818d67b415092cd660eecc0490b,
title = "Prophylaxis of eclamptic seizures: Current controversies",
abstract = "Treatment of this pathophysiologically poorly understood disease is controversial. Despite this uncertainty, the goals of management of the patient with preeclampsia and eclampsia are diagnosis, stabilization, and delivery of the baby. Stabilization refers to both mother and fetus and should include the prevention of eclampsia or the recurrence of eclamptic seizures. There are empiric data supporting the use of magnesium sulfate for the management of preeclampsia and eclampsia in North America, but there are few data to support its efficacy as a classic anticonvulsant. Until controlled trials are completed, we suggest that magnesium sulfate continue to be used in preeclampsia, with the addition of established anticonvulsant medications when eclampsia occurs. Data on established antiepileptic drugs such as diazepam and phenytoin support their use in treating patients with eclamptic seizures. As stated in an earlier review, 'in treating preeclampsia, magnesium sulfate therapy may have a role and may moderate factors leading to eclampsia. Whether magnesium sulfate therapy may have some as yet unproved effect on epileptogenic foci or seizure propagation is not the important issue for the physician caring for the eclamptic patient. Until adequately designed therapeutic trials are available, it is our opinion that treatment should be based on the use of anticonvulsant drugs of established efficacy in seizure control and prophylaxis (p. 1363).'",
author = "John Repke and Friedman, {S. A.} and Kaplan, {P. W.}",
year = "1992",
month = "1",
day = "1",
doi = "10.1097/00003081-199235020-00017",
language = "English (US)",
volume = "35",
pages = "365--374",
journal = "Clinical Obstetrics and Gynecology",
issn = "0009-9201",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Prophylaxis of eclamptic seizures : Current controversies. / Repke, John; Friedman, S. A.; Kaplan, P. W.

In: Clinical Obstetrics and Gynecology, Vol. 35, No. 2, 01.01.1992, p. 365-374.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Prophylaxis of eclamptic seizures

T2 - Current controversies

AU - Repke, John

AU - Friedman, S. A.

AU - Kaplan, P. W.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Treatment of this pathophysiologically poorly understood disease is controversial. Despite this uncertainty, the goals of management of the patient with preeclampsia and eclampsia are diagnosis, stabilization, and delivery of the baby. Stabilization refers to both mother and fetus and should include the prevention of eclampsia or the recurrence of eclamptic seizures. There are empiric data supporting the use of magnesium sulfate for the management of preeclampsia and eclampsia in North America, but there are few data to support its efficacy as a classic anticonvulsant. Until controlled trials are completed, we suggest that magnesium sulfate continue to be used in preeclampsia, with the addition of established anticonvulsant medications when eclampsia occurs. Data on established antiepileptic drugs such as diazepam and phenytoin support their use in treating patients with eclamptic seizures. As stated in an earlier review, 'in treating preeclampsia, magnesium sulfate therapy may have a role and may moderate factors leading to eclampsia. Whether magnesium sulfate therapy may have some as yet unproved effect on epileptogenic foci or seizure propagation is not the important issue for the physician caring for the eclamptic patient. Until adequately designed therapeutic trials are available, it is our opinion that treatment should be based on the use of anticonvulsant drugs of established efficacy in seizure control and prophylaxis (p. 1363).'

AB - Treatment of this pathophysiologically poorly understood disease is controversial. Despite this uncertainty, the goals of management of the patient with preeclampsia and eclampsia are diagnosis, stabilization, and delivery of the baby. Stabilization refers to both mother and fetus and should include the prevention of eclampsia or the recurrence of eclamptic seizures. There are empiric data supporting the use of magnesium sulfate for the management of preeclampsia and eclampsia in North America, but there are few data to support its efficacy as a classic anticonvulsant. Until controlled trials are completed, we suggest that magnesium sulfate continue to be used in preeclampsia, with the addition of established anticonvulsant medications when eclampsia occurs. Data on established antiepileptic drugs such as diazepam and phenytoin support their use in treating patients with eclamptic seizures. As stated in an earlier review, 'in treating preeclampsia, magnesium sulfate therapy may have a role and may moderate factors leading to eclampsia. Whether magnesium sulfate therapy may have some as yet unproved effect on epileptogenic foci or seizure propagation is not the important issue for the physician caring for the eclamptic patient. Until adequately designed therapeutic trials are available, it is our opinion that treatment should be based on the use of anticonvulsant drugs of established efficacy in seizure control and prophylaxis (p. 1363).'

UR - http://www.scopus.com/inward/record.url?scp=0026654953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026654953&partnerID=8YFLogxK

U2 - 10.1097/00003081-199235020-00017

DO - 10.1097/00003081-199235020-00017

M3 - Review article

C2 - 1638827

AN - SCOPUS:0026654953

VL - 35

SP - 365

EP - 374

JO - Clinical Obstetrics and Gynecology

JF - Clinical Obstetrics and Gynecology

SN - 0009-9201

IS - 2

ER -